Updated:
Avalon GloboCare Corp.
Avalon GloboCare Corp. is a publicly traded cell therapy developer led by CEO David Jin, focusing on CAR-T and exosome programs.
Avalon GloboCare Corp.
Avalon GloboCare Corp. was founded in 2014 by David Jin, who serves as CEO and directs the firm's strategic focus on cell and gene therapy. The company is structured as a publicly traded entity (NASDAQ: AVCO) rather than a closed-end family office or private investment vehicle, with its primary asset being a pipeline of preclinical and clinical-stage programs in immuno-oncology and exosome-based diagnostics and therapeutics. The firm pursues development through a combination of internal research and external collaborations. Programs include AVCO-101, an allogeneic CAR-T candidate targeting CD19 for hematologic malignancies, and AVCO-201, a mesenchymal stem cell therapy for neurodegenerative conditions. Avalon GloboCare has also partnered with academic institutions such as the University of Texas MD Anderson Cancer Center for exosome research. Geographically, the firm operates primarily in the United States, with some collaborative activities in China. As of 2025, the firm had not publicly disclosed its total assets under management or the size of its internal investment team. The company's market capitalization as of early 2025 was roughly $20M. No additional offices, philanthropic foundations, or operational subsidiaries have been confirmed in public filings. In January 2025, the firm announced a strategic collaboration with a Chinese biotech company to advance its exosome platform in Asia — a move that signals continued reliance on partnership-based development rather than internal capital deployment. Avalon GloboCare's structural differentiator is its dual identity as both a publicly traded corporation and a drug-development platform. That hybrid model means it relies on equity markets and licensing deals for capital, not committed family office funds — setting it apart from more conventional therapeutic-focused private vehicles.
General information
Firm type
Corporate Development Firm
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Freehold
Corporate office
Freehold, NJ, United States
Principals
David Jin
Chief Executive Officer
Frequently asked questions
Is Avalon GloboCare a family office or a publicly traded company?
Avalon GloboCare is a publicly traded corporation (NASDAQ: AVCO) that operates as a development-stage biotech firm. It is not structured as a family office, nor does it manage third-party capital. Its primary funding comes from equity markets, partnerships, and licensing deals.
What therapeutic areas does Avalon GloboCare focus on?
The firm focuses on cell-based therapeutics, specifically immuno-oncology (CAR-T and other cell therapies) and exosome-based diagnostics and therapeutics. Programs target hematologic malignancies, neurodegenerative conditions, and potential applications in regenerative medicine (per company filings and press releases).
How does Avalon GloboCare source its clinical programs?
Programs are developed both internally and through academic partnerships. Notable collaborations include a joint research agreement with the University of Texas MD Anderson Cancer Center for exosome biomarker development (per MD Anderson press release, 2018). The firm also in-licenses technology and partners with contract research organizations for clinical trials.
Has Avalon GloboCare disclosed its AUM or investment portfolio?
No. As a publicly traded development-stage company, Avalon GloboCare does not report AUM or an investment portfolio. Its market capitalization has fluctuated in the low tens of millions of dollars. The firm's financial statements are available through SEC filings.
Who leads investment decisions at Avalon GloboCare?
CEO David Jin directs strategic and investment decisions, including capital allocation for R&D and partnerships. The firm operates with a small executive team; full board composition is disclosed in SEC filings.
What is Avalon GloboCare's geographic footprint?
The firm is headquartered in Freehold, New Jersey, and operates primarily within the United States. It has disclosed collaborative activities with partners in China, though no physical office or subsidiary is confirmed in that region.
Does Avalon GloboCare have any approved commercial products?
No. As of mid-2025, all programs were in preclinical or clinical stages. The firm has not received FDA approval for any therapeutic product. Its exosome platform has shown early diagnostic potential, but no commercial tests are yet marketed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: